Table 2.
Assessment of prognostic value of blood-based parameters for response prediction.
| Total Study Population | Responders (n = 17) | Non-Responders (n = 16) | p Value | ||||
|---|---|---|---|---|---|---|---|
| Mean ± SD | Range | Mean ± SD | Range | Mean ± SD | Range | ||
| Erythrocytes (1012/L) | 4.4 ± 0.6 | 3.1–5.4 | 4.6 ± 0.5 | 4–5.4 | 4.1 ± 0.6 | 3.1–5.2 | 0.05 |
| Hemoglobin (g/dL) | 12.4 ± 1.4 | 9–15.1 | 12.9 ± 0.9 | 11.7–15.1 | 11.9 ± 1.6 | 9–14.3 | 0.182 |
| White blood cell count (109/L) | 6.9 ± 1.8 | 3.9–10.3 | 6.5 ± 1.2 | 3.9–8.6 | 7.4 ± 2.2 | 4.2–10.3 | 0.28 |
| Absolute neutrophil count (109/L) | 4.6 ± 1.5 | 2.4–8.3 | 4.1 ± 0.8 | 2.4–5.3 | 7.3 ± 0.8 | 6.8–8.3 | 0.002 |
| Absolute lymphocytes count (109/L) | 1.7 ± 0.7 | 0.6–2.8 | 1.7 ± 0.6 | 0.6–2.8 | 1.6 ± 0.8 | 0.8–2.3 | 0.871 |
| Thrombocytes (109/L) | 264.4 ± 95.8 | 131–623 | 232.6 ± 45.7 | 142–298 | 483.8 ± 760.9 | 131–623 | 0.094 |
| Thrombocyte volume (fL) | 10.5 ± 0.8 | 9–12 | 10.6 ± 0.8 | 9.1–12 | 10.2 ± 0.9 | 9–12 | 0.169 |
| CRP (mg/L) | 10.3 ± 16.2 | 0.08–62.8 | 3 ± 4.4 | 0.08–15.4 | 18.1 ± 20.4 | 0.9–62.8 | <0.001 |
| ALP (U/L) | 143 ± 128.6 | 31–714 | 110.5 ± 82.8 | 53–368 | 177.6 ± 159.7 | 31–714 | 0.045 |
| PLR | 178 ± 89.4 | 75.7–375 | 158.6 ± 71.3 | 75.7–316.4 | 250.7 ± 123.6 | 79.6–375 | 0.262 |
| NLR | 3.4 ± 2.1 | 1–8.5 | 2.8 ± 1.1 | 1–4.7 | 6.6 ± 3.1 | 3–8.5 | 0.056 |
| PCM | 3799 ± 7650 | 18–39,124 | 776 ± 1241 | 18–4451 | 7011 ± 10,092 | 254–39,124 | <0.001 |
| CRP-Albumin ratio | 0.2 ± 0.5 | 0–2.1 | 0.079 ± 0.115 | 0–0.4 | 0.46 ± 0.63 | 0.02–2.1 | 0.01 |
| SSR-TV (cm3) | 170.2 ± 192.1 | 12.1–797.3 | 105.7 ± 123.7 | 12.1–495.8 | 238.6 ± 229.6 | 12.4–797.3 | 0.068 |
| TL-SSR (cm3) | 3283.3 ± 4065.2 | 60.8–15,868 | 2095.1 ± 2250.4 | 139.1–8372.2 | 4545.7 ± 5153.1 | 60.8–15,868 | 0.26 |
ALP: Alkaline phosphatase; CRP: C-reactive protein; NLR: Neutrophil-lymphocyte ratio; PCM: Platelet × CRP multiplier; PLR: Platelet-lymphocyte ratio; SD: Standard deviation; SSR-TV: Somatostatin receptor-derived tumor volume; and TL-SSR: Total lesion somatostatin receptor expression.